TY - JOUR
T1 - Erlotinib-associated interstitial lung disease in advanced pancreatic carcinoma
T2 - A case report and literature review
AU - Macerelli, Marianna
AU - Mazzer, Micol
AU - Foltran, Luisa
AU - Cardellino, Giovanni Gerardo
AU - Aprile, Giuseppe
PY - 2015/7/1
Y1 - 2015/7/1
N2 - The combination of erlotinib and gemcitabine is a recognized option for patients with metastatic pancreatic cancer whose common adverse events such as skin rash, diarrhea, or fatigue are usually easily manageable. Interstitial lung disease (ILD) is a life-threatening toxicity reported in patients with non-small-cell lung cancers treated with epidermal growth factor receptor-tyrosine kinase inhibitors or gemcitabine. This side effect is extremely rare in patients with pancreatic cancer. We report fatal treatment-related ILD that occurred in a 67-year-old patient with metastatic pancreatic cancer. Risk factors and pathophysiology of ILD need further investigation but caution is highly recommended for patients with an underlying pulmonary disease when using erlotinib in monotherapy or combination therapy.
AB - The combination of erlotinib and gemcitabine is a recognized option for patients with metastatic pancreatic cancer whose common adverse events such as skin rash, diarrhea, or fatigue are usually easily manageable. Interstitial lung disease (ILD) is a life-threatening toxicity reported in patients with non-small-cell lung cancers treated with epidermal growth factor receptor-tyrosine kinase inhibitors or gemcitabine. This side effect is extremely rare in patients with pancreatic cancer. We report fatal treatment-related ILD that occurred in a 67-year-old patient with metastatic pancreatic cancer. Risk factors and pathophysiology of ILD need further investigation but caution is highly recommended for patients with an underlying pulmonary disease when using erlotinib in monotherapy or combination therapy.
KW - Advanced pancreatic cancer
KW - Erlotinib
KW - Interstitial lung disease
KW - Pulmonary ground-glass area
UR - http://www.scopus.com/inward/record.url?scp=84942902475&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942902475&partnerID=8YFLogxK
U2 - 10.5301/tj.5000327
DO - 10.5301/tj.5000327
M3 - Article
C2 - 25953445
AN - SCOPUS:84942902475
SN - 0300-8916
VL - 101
SP - e122-e127
JO - Tumori
JF - Tumori
IS - 4
ER -